Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJiazhen Yin

About this trial

With the help of the 'Traditional Chinese Medicine Specialty Alliance Platform-Multicenter RCT Clinical Research Database,' this platform can be used to conduct scientific research on various aspects of DKD, such as disease prediction, treatment effectiveness evaluation, and recurrence rate analysis, providing effective means to improve DKD remission rates, delay disease progression, and enhance patients' quality of life. By selecting the Jiade Yishen Xiaozheng Qufang formula and conducting multicenter, prospective, double-blind RCT studies, its clinical value in improving DKD remission rates can be verified. With the support of scientific research, DKD treatment strategies can be optimized, therapeutic efficacy improved, recurrence rates reduced, and disease progression delayed, thereby enhancing patients' quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Meets the clinical diagnostic criteria for diabetic nephropathy;

Aged 18-75 years, any gender;

eGFR >45 ml/min/1.73m²;

24-hour urine protein <2.0 g/day;

Disqualifiers

Acute kidney injury or renal function impairment caused by other reasons (recent rapid decline in renal function, or kidney damage caused by drugs, infections, etc.);

Other primary or secondary kidney diseases (such as systemic lupus erythematosus, polycystic kidney disease, etc.);

Uncontrolled severe complications (such as severe cardiovascular disease, uncontrolled hypertension, severe infections, etc.);

Critical organ failure (severe diseases of the heart, liver, or lungs);

Trial design

Design model

Parallel

Treatments tested in this trial

  • Jiajian Yishen Xiaozheng Qufeng Granules

    Drug

    Involving unlisted drugs, vaccines, medical devices, and other products;Unlisted product type: Medicine;Unlisted product name: Jia Jian Yi Shen Xiao Zheng Qu Feng Fang Granules;Unlisted Product Preparation Organization: Jiangyin Tianjiang Pharmaceutical Co., Ltd.;Type of preparation institution for unlisted products: Domestic (within China).

Treatment groups

198 Participants
are divided into 2 treatment groups
Group A: Experimental groupExperimental treatment 1 intervention
Group B: Control groupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

UACR/UAER/24-hour urinary protein returns to normal or decreases by 50% compared with before.

Time frame
Western medical efficacy evaluation will be conducted at weeks 0, 4, 8, 12, 16, 20, and 24

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jiazhen Yin

Lead sponsor

Hangzhou Hospital of Traditional Chinese Medicine

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: